Q-omics provides the consensus-scored ANGPTL1 profile across patient tissues and cancer cell-line models. ANGPTL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ANGPTL1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, ANGPTL1 protein abundance shows 27,719 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRC, and GBM as cancer lineages where ANGPTL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANGPTL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANGPTL1 survival associations across molecular data types. ANGPTL1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANGPTL1 RNA expression–survival associations across cancer types. High ANGPTL1 expression shows unfavorable associations in BLCA and LUSC, but favorable associations in KIRC, SKCM, BRCA and LIHC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify BLCA as the clearest survival context for ANGPTL1 RNA expression.
This table summarizes ANGPTL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ANGPTL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANGPTL1 shows lower tumor expression in KIRC, BLCA, THCA, COAD, HNSC and KIRP. The KIRC box plot shows higher ANGPTL1 RNA expression in normal versus tumor tissue (log2 FC = −3.275, t-test p < 0.001).
This table shows molecular features associated with ANGPTL1 in patient tissues and cancer cell lines. In patient samples, ANGPTL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANGPTL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
